Meyka Pro banner
Akili, Inc.

Akili, Inc. (NASDAQ: AKLI) Stock Competitors & Peer Comparison

See AKLI's competitors and their performance on the NASDAQ and across the wider stock market.

AKLINASDAQ
HealthcareMedical - Healthcare Information Services
$0.43
$0.001(0.25%)
U.S. Market opens in 64h 28m

Peer Comparison Table: Medical - Healthcare Information Services Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for AKLI and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
AKLI$0.43+0.25%34.1M-0.71-$0.61N/A
VEEV$189.24-4.14%30.7B22.71$8.33N/A
GEHC$62.04-1.26%28.2B13.61$4.56+0.23%
GEHCV$56.00-4.08%25.5BN/AN/AN/A
BTSGU$239.04+3.24%14.4B216.59$1.11N/A
BTSG$72.56+2.92%14.2B58.52$1.24N/A
SGFY$30.49+0.07%8.9B70.91$0.43N/A
TEM$48.98+1.18%8.5B-97.96-$0.50N/A
HQY$97.77-1.12%8.2B22.84$4.28N/A
HNGE$84.35-3.82%6.5B43.22$1.95N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Veeva Systems Inc. (NYSE: VEEV)

AKLI vs VEEV Comparison July 2026

Akili, Inc. (NASDAQ: AKLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, VEEV has a market cap of 30.7B. Regarding current trading prices, AKLI is priced at $0.43 on the NASDAQ, while VEEV trades at $189.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas VEEV's P/E ratio is 22.71. In terms of profitability, AKLI's ROE is -0.70%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to VEEV. This indicates lower risk in terms of short-term price fluctuations for AKLI.Check VEEV's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions